Extended 72-hour patency capsule protocol improves functional patency rates in high-risk patients undergoing capsule endoscopy

Table 1 Demographics

Study population demographics	n = 135
Male, n (%)	60 (44)
female, n (%)	75 (56)
Age, year (IQR)	50.1 (29.0)
Indication for capsule endoscopy
Suspected Crohn's disease, n (%)	67 (49.7)
Crohn's assessment, n (%)	30 (22.5)
IDA, n (%)	24 (17.7)
GI bleeding, n (%)	3 (2.4)
Other, n (%)	10 (6.5)

IDA: Iron deficiency anaemia; GI: Gastrointestinal.

Table 2 Indication for patency, n (%)

	Overall group, n = 135	Extended patency group, n = 69	P value
Previous surgery	43 (31.9)	24 (34.8)	0.7686
Crohn’s disease	32 (23.7)	15 (21.7)	0.8651
Radiology	18(13.3)	10 (14.5)	0.8344
NSAIDs	18 (13.3)	8 (11.6)	0.8286
Endoscopic findings	9 (6.7)	5 (7.2)	-
Obstructive symptoms	9 (6.7)	4 (5.8)	-
Prior abdominal radiation	3 (2.2)	1 (1.4)	-
No clear indication	3 (2.2)	2 (2.9)	-

NSAIDs: Non-steroidal anti-inflammatory drugs.

Table 3 Capsule findings post patency, n = 78

Items	n (%)
Normal study	39 (50.0)
Enteritis/ileitis	27 (34.6)
Angiodysplasia	2 (2.6)
Duodenitis	3 (3.8)
Small bowel polyp	2 (2.6)
Colonic polyp	2 (2.6)
Submucosal bulge	1 (1.3)
Meckel’s diverticulum	1 (1.3)
Gastric retention	1 (1.3)

Table 4 Small bowel transit time

	n	SBTT (mean, minute)	SD
Patency at 28 hours	66	241	145
Patency at 72 hours	12	243	102

SBTT: Small bowel transit time.